Avalo Therapeutics AVTX Cash Flow Statement (2014-2026)

NASDAQ AVTX
$12.81 +0.45 (+3.60%)
As of: Oct 21, 2026 · 11:41 AM EDT
Reported Financials

Avalo Therapeutics Quarterly Cash Flow Statement

Periods 48 quarters
Latest Jun 2026

Avalo Therapeutics reported cash from operations of -$20.00M and free cash flow of -$20.00M for the quarter ended Jun 2026, down 75.6% year over year. This cash flow statement covers 48 quarters of results from Sep 2014 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-17.40M-19.20M-22.05M-12.99M3.19M-9.81M-9.96M-8.19M-5.23M-8.17M-121.29M98.46M23.04M-35.34M-13.15M-20.77M-30.63M-13.76M-19.63M-36.36M
Depreciation and DepletionDep. & Depletion
Depreciation, Depletion & Amortization
Amortization of Deferred ChargesAmort. Deferred Charges
0.34M0.35M0.35M0.34M0.35M0.35M0.35M0.35M1.13M
Depreciation & Amortization (CF)Dep. & Amort.
0.46M0.30M0.07M0.03M0.03M0.04M0.03M0.04M0.04M0.04M0.03M0.03M0.03M0.07M0.14M0.13M0.06M0.02M0.02M0.02M
Share-based CompensationStock Comp.
1.76M1.89M5.31M0.67M0.73M0.84M0.86M0.89M0.95M0.78M0.63M0.47M1.85M2.90M3.24M2.72M3.15M4.51M3.58M5.31M
Deferred Taxes
0.01M-0.02M0.01M0.01M0.01M0.01M0.01M0.01M0.01M-0.01M0.01M0.01M-0.01M0.11M0.01M0.02M0.01M0.13M0.01M0.02M
Gains from Investment SecuritiesGains Investment
0.12M-5.04M-1.10M9.19M-0.38M2.53M-12.53M24.20M-0.48M1.01M
Asset Writedowns and ImpairmentWritedown
Other non-cash itemsOther Non-Cash
106.81M-111.94M-36.03M21.15M6.57M
Change in Working Capital
Change in ReceivablesChange Receivables
-2.69M-0.38M-0.12M-0.39M-0.54M0.04M-0.04M
Change in InventoryChange Inventory
0.00M0.02M-0.01M0.00M0.00M0.00M0.00M0.00M-0.02M
Change in Account PayablesChange Payables
1.32M-0.20M0.39M-1.59M-0.72M1.44M2.68M-4.81M0.04M-0.34M0.47M-0.26M1.16M-1.53M0.40M1.69M-1.89M-0.34M0.22M2.99M
Change in Accured ExpensesChange Accured Exp.
-2.31M0.65M-2.29M-1.25M0.39M-0.49M-4.94M-0.69M-2.46M-0.96M-1.65M0.40M-0.86M1.00M-1.70M1.99M1.02M5.35M-1.50M6.63M
Change in TaxesChange Taxes
Change in Other Operating AssetsOther Assets Change
3.14M1.23M-1.98M-0.94M-0.76M0.78M-0.73M-1.34M1.34M-1.50M0.05M1.44M1.78M0.08M-2.49M0.07M0.24M4.77M-0.23M0.92M
Change in Other Operating LiabilitiesOther Liabilities Change
-0.02M0.01M0.03M-0.01M0.43M-0.37M0.01M-0.29M0.07M-0.11M-0.34M0.08M0.19M-0.01M0.01M0.01M-0.04M-0.06M-0.03M-0.02M
Other Working Capital ChangesOther WC Changes
-3.15M-1.22M2.01M0.93M1.19M-1.14M0.73M1.06M-1.27M1.39M-0.40M-1.36M-1.59M-0.08M2.50M-0.06M-0.27M-4.84M0.20M-0.94M
Other Operating ActivitiesOther Ops.
-0.51M0.51M-4.81M
Cash from OperationsCash from Ops.
-16.29M-17.10M-16.07M-12.47M5.73M-3.94M-10.05M-11.03M-6.84M-2.77M-6.20M-16.28M-11.53M-15.04M-9.46M-11.39M-16.37M-14.29M-17.70M-20.00M
Investing Activities
Capital ExpendituresCapex
0.08M0.01M0.06M0.04M0.16M
Sales of Property, Plant and EquipmentPP&E (Sale)
0.03M
Change in Property, Plant and EquipmentChange in PP&E
-0.08M-0.01M-0.06M-0.04M-0.13M
Acquisitions
-0.36M
Divestments
Net of Acquisitions & DivestmentsNet Acquisitions
0.36M
Purchase of InvestmentsInvestments Purchased
23.76M19.10M
Sale and Maturity of InvestmentsInvestments Sold
10.50M21.50M25.51M23.88M
Other Investing ActivitiesOther investing
Cash from Investing ActivitiesCash from Investing
-0.08M-0.01M-0.06M-0.04M-0.13M0.36M-70.86M-13.26M2.40M25.51M-329.93M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt IssuancesLT Debt Issuance
Long-Term Debt RepaymentsLT Debt Repayment
15.00M-14.81M
Non-Current Debt
-15.00M14.81M
Net Debt Issuances and RepaymentsNet Debt Issuance
-15.00M14.81M
Change in Capital Stock
Common Stock IssuedStock Issued
34.36M0.08M0.03M-14.72M13.75M6.60M25.90M0.00M69.44M0.04M15.52M2.18M5.30M
Net Shares Issued and RepurchasedNet Shares Issued
34.36M0.08M0.03M-14.72M13.75M6.60M25.90M0.00M69.44M0.04M15.52M2.18M5.30M
Net Equity Issued and RepurchasedNet Equity Issued
34.36M0.08M0.03M-14.72M13.75M6.60M25.90M0.00M69.44M0.04M15.52M2.18M5.30M
Other financing activitiesOther financing
-7.01M-0.47M-1.73M-0.51M0.00M-0.46M-0.78M
Cash from Financing ActivitiesCash from Financing
47.64M0.08M-14.78M0.08M13.75M0.60M10.70M0.00M108.61M-0.47M67.71M-0.47M14.37M0.69M1.40M410.21M
Additional items
Change in Cash
31.27M-17.03M-16.07M-27.31M5.69M-3.86M3.56M-10.43M3.86M-2.77M102.77M-16.76M-11.53M52.67M-9.46M-82.72M-15.26M-11.16M9.21M60.30M
Ending Cash Balance
71.90M54.86M38.80M11.49M17.18M13.32M16.88M6.45M10.31M7.55M110.31M93.56M82.03M134.70M125.24M42.52M27.26M16.11M25.32M85.61M
Free Cash FlowFCF
-16.37M-17.11M-16.07M-12.53M5.69M-3.94M-10.21M-11.03M-6.84M-2.77M-6.20M-16.28M-11.53M-15.04M-9.46M-11.39M-16.37M-14.29M-17.70M-20.00M
Net Cash FlowNCF
31.27M-17.03M-16.07M-27.31M5.69M-3.86M3.56M-10.43M3.86M-2.77M102.77M-16.76M-11.53M52.67M-9.46M-82.72M-15.26M-11.20M9.20M60.28M
Interest Paid
0.80M0.79M0.83M0.83M0.60M0.68M0.70M0.74M0.49M
Income Taxes PaidTaxes Paid

Avalo Therapeutics Cash Flow Statement API

Pull Avalo Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=AVTX&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY